31 / 71 d uring 2016, novo added four public and 10 private companies to its venture portfolio. in the majority of the private financings, novo a/s was lead or co-lead investor. our new portfolio companies develop therapies for a variety of indications, including anti-infectives, cancer immunotherapy, genetics, respiratory
